tldrdailynews.com logo
Tag

Pharma

All articles tagged with #pharma

Safety signals pause autoimmune CAR-T trials at Novartis and BMS
pharma4 days ago

Safety signals pause autoimmune CAR-T trials at Novartis and BMS

Novartis and Bristol Myers Squibb have paused several autoimmune CAR-T trials after inflammatory safety events were seen, including IEC-HS cases in rap-cel studies across lupus, myasthenia gravis, and multiple sclerosis, and transient inflammatory events in zola-cel programs. Both companies say the pauses are precautionary while safety data are reviewed with regulators, with cancer trials continuing. A faster production approach for CAR-Ts may influence toxicity, but the companies emphasize ongoing monitoring and a potential quick resume once reviews are complete.

via BioPharma Dive|
#autoimmune-disease#car-t#pharma
Sentivera inks up-to-$1.5B deal for inflammatory drug with Haisco
business10 days ago

Sentivera inks up-to-$1.5B deal for inflammatory drug with Haisco

Sentivera, formed by Arch Venture Partners and Population Health Partners after Metsera’s stealth exit, licensed an inflammatory-disease drug candidate to Haisco Pharmaceutical for up to about $1.5 billion, with $40 million cash upfront and stock valued at roughly $36 million for a 17.5% stake; Haisco retains Greater China rights, while Sentivera is positioned to advance the asset globally as a small-molecule therapy targeting Type 2 inflammatory diseases such as asthma and eczema.

via Fierce Biotech|
#biotech#business#inflammation
AstraZeneca and Bristol Myers Squibb reportedly eye record $400B merger
business1 month ago

AstraZeneca and Bristol Myers Squibb reportedly eye record $400B merger

UK drugmaker AstraZeneca and US rival Bristol Myers Squibb are reportedly weighing a merger valued at about $400 billion, potentially the largest deal in history. Talks have been ongoing for months with no commitment or comment from either side, and the deal would reshape both companies’ cancer-drug portfolios and strategic positioning in the pharma industry.

via CNBC|
#astrazeneca#bristol-myers-squibb#business
Cold-Chain Shipping Roars as UPS, FedEx and Peers Tap the Healthcare Boom
business1 month ago

Cold-Chain Shipping Roars as UPS, FedEx and Peers Tap the Healthcare Boom

Logistics giants like UPS, FedEx, DHL and others are expanding temperature-controlled capabilities to service a booming healthcare market driven by GLP-1 therapies (e.g., Ozempic/Wegovy, Mounjaro/Zepbound) and other biologics, investing in refrigerated facilities and AI-enabled tracking to ensure end-to-end cold-chain reliability. Demand is projected to grow about 8.3% CAGR to 2033, reaching roughly $39 billion, as companies report rising healthcare revenues and shift toward specialized therapies and patient-focused delivery.

via CNBC|
#business#cold-chain#glp-1
GSK pivots to oncology expansion with $10.6B Nuvalent takeover
business2 months ago

GSK pivots to oncology expansion with $10.6B Nuvalent takeover

GSK agreed to acquire Nuvalent for $10.6 billion in cash, paying about $124 per share (roughly a 40% premium) to bolster its oncology pipeline and offset expected HIV revenue declines when its best-selling HIV medicine loses exclusivity in 2028. Nuvalent brings late-stage lung-cancer assets neladalkib and zidesamtinib, plus an early-stage and preclinical portfolio, with potential blockbusters if approved by the FDA. The deal would be GSK’s second-largest ever and signals a shift toward larger biotech deals amid strong M&A activity, with guidance unchanged for 2026 and growth anticipated from 2027.

via CNBC|
#biotech#business#lung-cancer
BMS inks $15B China-backed deal to fast-track Hengrui assets
business3 months ago

BMS inks $15B China-backed deal to fast-track Hengrui assets

Bristol Myers Squibb is striking a broad deal with Hengrui Pharma worth up to $15.2 billion, featuring $600 million upfront for 13 early-stage programs, ex-China rights to four oncology/hematology assets, and joint discovery on five candidates; Hengrui will gain access to BMS immunology assets in China, Hong Kong and Macau and lead early development to proof of concept, in a move that leverages China's reportedly faster timelines (50–70% quicker) to clinical proof of concept.

via Fierce Biotech|
#biotech#bms#business
Pharma Bets on Deals as Patents Fade and Pricing Shifts Shape 2026
business7 months ago

Pharma Bets on Deals as Patents Fade and Pricing Shifts Shape 2026

At the JPMorgan Healthcare Conference, pharma executives signaled that 2026 could begin a recovery as pricing deals reduce uncertainty and patent expirations drive more dealmaking; leaders from Merck, Bristol Myers Squibb, Novo Nordisk, AstraZeneca and Pfizer outlined plans to offset price pressure with new products and BD activity, while vaccine policy shifts add political headwinds.

via CNBC|
#business#dealmaking#drug-pricing